Mafalda Oliveira

Also affiliated with Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer”.

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3953

N/A

3.2DataRank · unranked

108 citations

Kenji Tamura, Mafalda Oliveira, Eva Ciruelos, Ingrid A. Mayer, Marie‐Paule Sablin +23 more

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Nature Communications(2022)10.1038/s41467-022-32828-6

N/A

0.721DataRank · unranked

121 citations

Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel González-Pérez, Mafalda Oliveira +33 more

Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer

Cancer Cell(2020)10.1016/j.ccell.2020.08.016

N/A

0DataRank · unranked

54 citations

Alan J. Wright, Paula D’Santos, De‐En Hu, Richard L. Hesketh, Yaniv Lubling +19 more

Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3324

N/A

0DataRank · unranked

41 citations

Marta Palafox, Laia Monserrat, Fara Brasó‐Maristany, Andreu Òdena, Mònica Sánchez-Guixé +26 more

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Research Square(2021)10.21203/rs.3.rs-236645/v1

N/A

0DataRank · unranked

12 citations

Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel González-Pérez, Mafalda Oliveira +33 more

Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

Cancer Research(2022)10.1158/0008-5472.can-21-2409

N/A

0DataRank · unranked

98 citations

Andrea Herencia-Ropero, Alba Llop‐Guevara, Flaminia Pedretti, Alejandro Moles‐Fernández, Cristina Viaplana +34 more

Data from Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

(2023)10.1158/0008-5472.c.6513876.v1

N/A

0DataRank · unranked

0 citations

Andrea Herencia-Ropero, Alba Llop‐Guevara, Flaminia Pedretti, Alejandro Moles‐Fernández, Cristina Viaplana +34 more

A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

The Lancet Oncology(2020)10.1016/s1470-2045(20)30450-2

N/A

0DataRank · unranked

75 citations

Valentina Guarneri, Laia Paré, Gaia Griguolo, Tomás Pascual, Maria Vittoria Dieci +34 more